Status:
UNKNOWN
Ceftazidime Pharmacokinetic in Cerebrospinal Fluid Between Continuous and Intermittent Administration
Lead Sponsor:
University Hospital, Clermont-Ferrand
Conditions:
Pseudomonas Aeruginosa Meningitis
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
Meningitis is an infection where morbidity and mortality depend on the delay of the initial treatment for a good prognostic. The antibiotherapy rapidity allows to decrease the mortality. Intermittent ...
Detailed Description
This study will compare the administration of ceftazidime by intermittent intravenous injections (29 mg/kg 30min ×3/day) and by continuous infusion (86 mg/kg/24 h, preceded by 29 mg/kg/30 min). The ma...
Eligibility Criteria
Inclusion
- patients aged over 18 years old,
- patients hospitalised for a cerebrolesion associated to a hydrocephalus drained by an external ventricular derivation, an acquired pneumopathy under mechanic ventilation since more 7 days in the department of neurological intensive care
Exclusion
- patients treated by ceftazidime 15 days before the beginning of this study
Key Trial Info
Start Date :
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2009
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT00752882
End Date
June 1 2009
Last Update
January 19 2011
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.